<DOC>
	<DOC>NCT01240161</DOC>
	<brief_summary>The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.</brief_summary>
	<brief_title>Personalized Translational Platform for Biomarker Discovery in Brain Tumors</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT Anticipated survival ≥6 months Able to give informed consent Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia Male or Female Prior radiation therapy and chemotherapy to the brain Active intracranial infection or nonglial brain mass. Recent large intracranial hemorrhage (&lt;1 month) Expected survival &lt;6 months Pregnant or nursing Renal failure Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>FLT</keyword>
	<keyword>PET</keyword>
</DOC>